Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Vibeke Strand, MD

Articles by Vibeke Strand, MD

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

ByVibeke Strand, MD,Colby Evans, MD,Allan Gibofsky, MD, JD

November 1st 2022

Biosimilar medicines: what are they and how are they used?

ByVibeke Strand, MD,Colby Evans, MD,Allan Gibofsky, MD, JD

November 1st 2022

Plain Language Summary

Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

What do patients and health care providers still need to know about biosimilar medicines?

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

Plain Language Summary

eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective

ByColby Evans, MD,Allan Gibofsky, MD, JD,Vibeke Strand, MD

November 1st 2022

What are the current challenges to wider biosimilar use in the United States?

ByColby Evans, MD,Allan Gibofsky, MD, JD,Vibeke Strand, MD

November 1st 2022

Plain Language Summary

Improved Health-related Quality of Life With Effective Disease-modifying Antirheumatic Drugs: Evidence From Randomized Controlled Trials

ByVibeke Strand, MD,Jasvinder A. Singh, MD, MPH

April 15th 2008

Latest Updated Articles

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective
November 1st 2022
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
November 1st 2022
Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys
November 1st 2022
Improved Health-related Quality of Life With Effective Disease-modifying Antirheumatic Drugs: Evidence From Randomized Controlled Trials
April 15th 2008

Trending on AJMC

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD